Literature DB >> 19763426

Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development.

Yan Cheng1, Youjun Feng, Ping Luo, Jiang Gu, Shu Yu, Wei-jun Zhang, Yan-qing Liu, Qing-Xu Wang, Quan-ming Zou, Xu-hu Mao.   

Abstract

Shiga toxin 2 (Stx2) is a major virulence factor for enterohemorrhagic Escherichia coli (EHEC), which is encoded by lambda lysogenic phage integrated into EHEC chromosome. Stx2Al, Al subunit of Stx2 toxin has gathered extensive concerns due to its potential of being developed into a vaccine candidate. However, the substantial progress is hampered in part for the lack of a suitable in vitro expression system. Here we report use of the prokaryotic system pET-28a::espA-Stx2Al/BL21 to carry out the fusion expression of Stx2Al which is linked to E. coli secreted protein A (EspA) at its N-terminus. Under the IPTG induction, EspA-Stx2Al fusion protein in the form of inclusion body was obtained successfully, whose expression level can reach about 40% of total bacterial protein at 25 degrees C, much higher than that at 37 degrees C. Western blot test suggested the refolded fusion protein is of excellent immuno-reactivity with both monoclonal antibodies, which are specific to EspA and Stx2Al, respectively. Anti-sera from Balb/c mice immunized with the EspA-Stx2Al fusion protein were found to exhibit strong neutralization activity and protection capability in vitro and in vivo. These data have provided a novel feasible method to produce Stx2Al in large scale in vitro, which is implicated for the development of multivalent subunit vaccines candidate against EHEC 0157:H7 infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763426     DOI: 10.1007/s12275-009-0116-8

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  31 in total

1.  Supermolecular structure of the enteropathogenic Escherichia coli type III secretion system and its direct interaction with the EspA-sheath-like structure.

Authors:  K Sekiya; M Ohishi; T Ogino; K Tamano; C Sasakawa; A Abe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

2.  Secretion of extracellular proteins by enterohemorrhagic Escherichia coli via a putative type III secretion system.

Authors:  K G Jarvis; J B Kaper
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 4.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections.

Authors:  Diana Karpman; Zivile D Békássy; Ann-Christine Sjögren; Maria S Dubois; Mohamed A Karmali; Mariola Mascarenhas; Karen G Jarvis; Lisa J Gansheroff; Alison D O'Brien; Gerald S Arbus; James B Kaper
Journal:  Pediatr Nephrol       Date:  2002-03       Impact factor: 3.714

6.  Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.

Authors:  Marie E Fraser; Masao Fujinaga; Maia M Cherney; Angela R Melton-Celsa; Edda M Twiddy; Alison D O'Brien; Michael N G James
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

8.  [Preparation and characterization of monoclonal antibody against Enterohemorrhagic Escherichia coli O157:H7 EspA].

Authors:  Shu Yu; Ping Luo; Hong-zhang Chen; Hai-xia Li; Xu-hu Mao
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2007-07

9.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

10.  Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice.

Authors:  Hiroki Takahashi; Keiko Sasaki; Miyuki Takahashi; Naoko Shigemori; Shyunichi Honda; Hideyuki Arimitsu; Sadayuki Ochi; Naoya Ohara; Takao Tsuji
Journal:  Vaccine       Date:  2006-02-13       Impact factor: 3.641

View more
  10 in total

Review 1.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

Authors:  David A Montero; Felipe Del Canto; Juan C Salazar; Sandra Céspedes; Leandro Cádiz; Mauricio Arenas-Salinas; José Reyes; Ángel Oñate; Roberto M Vidal
Journal:  NPJ Vaccines       Date:  2020-03-12       Impact factor: 7.344

3.  In silico analysis of Shiga toxins (Stxs) to identify new potential vaccine targets for Shiga toxin-producing Escherichia coli.

Authors:  Maryam Golshani; Mana Oloomi; Saeid Bouzari
Journal:  In Silico Pharmacol       Date:  2017-05-22

4.  Oral Administration with Live Attenuated Citrobacter rodentium Protects Immunocompromised Mice from Lethal Infection.

Authors:  Shuyu Wang; Xue Xia; Yue Liu; Fengyi Wan
Journal:  Infect Immun       Date:  2022-07-05       Impact factor: 3.609

Review 5.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

6.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

Review 7.  Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.

Authors:  Sabrina Mühlen; Petra Dersch
Journal:  Front Cell Infect Microbiol       Date:  2020-05-06       Impact factor: 5.293

8.  Escherichia coli outer membrane protein F (OmpF): an immunogenic protein induces cross-reactive antibodies against Escherichia coli and Shigella.

Authors:  Xiao Wang; Da Teng; Qingfeng Guan; Ruoyu Mao; Ya Hao; Xiumin Wang; Junhu Yao; Jianhua Wang
Journal:  AMB Express       Date:  2017-07-19       Impact factor: 3.298

Review 9.  Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.

Authors:  Maricarmen Rojas-Lopez; Ricardo Monterio; Mariagrazia Pizza; Mickaël Desvaux; Roberto Rosini
Journal:  Front Microbiol       Date:  2018-03-20       Impact factor: 5.640

10.  Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

Authors:  David A Montero; Felipe Del Canto; Juan C Salazar; Sandra Céspedes; Leandro Cádiz; Mauricio Arenas-Salinas; José Reyes; Ángel Oñate; Roberto M Vidal
Journal:  NPJ Vaccines       Date:  2020-03-12       Impact factor: 7.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.